Deciphera Pharmaceuticals Llc Stock Current Valuation
| DCPHDelisted Stock | USD 13.32 0.36 2.63% |
Valuation analysis of Deciphera Pharmaceuticals helps investors to measure Deciphera Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Deciphera Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Deciphera Pharmaceuticals is based on 3 months time horizon. Increasing Deciphera Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Deciphera Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Deciphera Stock. However, Deciphera Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 13.32 | Real 11.65 | Hype 13.32 | Naive 13.47 |
The intrinsic value of Deciphera Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Deciphera Pharmaceuticals' stock price.
Estimating the potential upside or downside of Deciphera Pharmaceuticals LLC helps investors to forecast how Deciphera stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Deciphera Pharmaceuticals more accurately as focusing exclusively on Deciphera Pharmaceuticals' fundamentals will not take into account other important factors: Deciphera Pharmaceuticals LLC Company Current Valuation Analysis
Deciphera Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Deciphera Pharmaceuticals Current Valuation | 1.97 B |
Most of Deciphera Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Deciphera Pharmaceuticals LLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Deciphera Pharmaceuticals LLC has a Current Valuation of 1.97 B. This is 86.32% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is 88.18% higher than that of the company.
Deciphera Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Deciphera Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Deciphera Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Deciphera Pharmaceuticals by comparing valuation metrics of similar companies.Deciphera Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Deciphera Fundamentals
| Return On Equity | -0.5 | |||
| Return On Asset | -0.27 | |||
| Profit Margin | (1.09) % | |||
| Operating Margin | (1.09) % | |||
| Current Valuation | 1.97 B | |||
| Shares Outstanding | 86.48 M | |||
| Shares Owned By Insiders | 28.48 % | |||
| Shares Owned By Institutions | 72.03 % | |||
| Number Of Shares Shorted | 3.92 M | |||
| Price To Earning | (6.78) X | |||
| Price To Book | 7.00 X | |||
| Price To Sales | 12.65 X | |||
| Revenue | 163.36 M | |||
| Gross Profit | (62.55 M) | |||
| EBITDA | (210.96 M) | |||
| Net Income | (194.94 M) | |||
| Cash And Equivalents | 383.85 M | |||
| Cash Per Share | 5.74 X | |||
| Total Debt | 25.88 M | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 6.02 X | |||
| Book Value Per Share | 3.85 X | |||
| Cash Flow From Operations | (146.7 M) | |||
| Short Ratio | 1.05 X | |||
| Earnings Per Share | (2.21) X | |||
| Price To Earnings To Growth | (0.32) X | |||
| Target Price | 27.52 | |||
| Number Of Employees | 355 | |||
| Beta | 0.18 | |||
| Market Capitalization | 2.21 B | |||
| Total Asset | 473.57 M | |||
| Retained Earnings | (1.43 B) | |||
| Working Capital | 280.82 M | |||
| Current Asset | 70.55 M | |||
| Current Liabilities | 5.98 M | |||
| Net Asset | 473.57 M |
About Deciphera Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Deciphera Pharmaceuticals LLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Deciphera Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Deciphera Pharmaceuticals LLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Deciphera Stock
If you are still planning to invest in Deciphera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Deciphera Pharmaceuticals' history and understand the potential risks before investing.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |